Product
EGFRt/BCMA-41BBz CAR T
1 clinical trial
1 indication
Indication
Multiple MyelomaClinical trial
A Phase I Trial of B-cell Maturation Antigen (BCMA) Targeted EGFRt/BCMA-41BBz Chimeric Antigen Receptor (CAR) Modified T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma (MM)Status: Active (not recruiting), Estimated PCD: 2025-02-01